Thromb Haemost 2002; 87(03): 409-414
DOI: 10.1055/s-0037-1613018
Review Article
Schattauer GmbH

Factor XIII – Circulating Levels and the Val34Leu Polymorphism in the Healthy Male Relatives of Patients with Severe Coronary Artery Disease

Joseph D. Mills
1   Academic Unit of Molecular Vascular Medicine, University of Leeds, UK
,
Michael W. Mansfield
1   Academic Unit of Molecular Vascular Medicine, University of Leeds, UK
,
Peter J. Grant
1   Academic Unit of Molecular Vascular Medicine, University of Leeds, UK
› Author Affiliations
Further Information

Publication History

Received 12 June 2001

Accepted after resubmission 05 December 2001

Publication Date:
14 December 2017 (online)

Summary

We aimed to investigate whether increased levels of FXIII and/or a low prevalence of the protective Leu allele (of the Val34Leu FXIII polymorphism) occur in relatives of patients with severe CAD. 185 healthy male relatives aged 65 or less were recruited from 125 patients with multi-vessel CAD and compared to 185 healthy, agematched controls. The relatives and controls were similar in terms of clinical parameters. FXIII B-subunit levels were elevated in relatives, 1.11 µg/mL (1.08-1.14), compared with controls, 1.00 µg/mL (0.97-1.04), P<0.0001 but FXIII A2B2 levels did not differ between the groups. There was a strong correlation between FXIII B-subunit and the insulin resistance syndrome, however, adjusted B-subunit levels remained significantly higher in relatives. There was no difference in genotype frequency at the FXIII Val34Leu polymorphism between relatives and controls. FXIII B-subunit levels are elevated in the relatives of CAD patients and this is independent of other cardiovascular risk factors.

 
  • References

  • 1 Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets: molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248: 1395-407.
  • 2 Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999; 99: 299-304.
  • 3 Francis CW, Connaghan DG, Scott WL, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987; 75: 1170-7.
  • 4 Kloczko J, Wojtukiewicz M, Bielawiec M, Zarzycka B, Kinalska I. Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy. Acta Haematol 1986; 76: 81-5.
  • 5 Mansfield MW, Kohler HP, Ariens RA, McCormack LJ, Grant PJ. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives. Diabetes Care 2000; 23: 703-5.
  • 6 Kohler HP, Stickland MH, Ossei-Gerning N, Carter AM, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8.
  • 7 Wartiovaara U, Perola M, Mikkola H, Totterman K, Savolainen V, Penttila A, Grant PJ, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 1999; 142: 295-300.
  • 8 Franco RF, Pazin-Filho A, Tavella MH, Simoes MV, Marin-Neto JA, Zago MA. Factor XIII val34leu and the risk of myocardial infarction. Haematologica 2000; 85: 67-71.
  • 9 Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
  • 10 Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-8.
  • 11 Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
  • 12 Friedlander Y, Kark JD, Stein Y. Family history of myocardial infarction as an independent risk factor for coronary heart disease. Br Heart J 1985; 53: 382-7.
  • 13 Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary Risk Associated with Age and Sex of Parental Heart Disease in the Framingham Study. Am J Cardiol 1989; 64: 555-9.
  • 14 Shea S, Ottman R, Gabrieli C, Stein Z, Nichols A. Family History as an Independent Risk Factor for Coronary Artery Disease. J Am Coll Cardiol 1984; 04: 793-801.
  • 15 Marbet GA, Duckert F. Fibrinogen. In: ECAT assay procedures. A manual of laboratory techniques. Jespersen J, Bertina RM, Haverkate F. (eds). Kluwer Academic Publishers; 1992: 47-56.
  • 16 Komanasin N, Futers TS, Ariens RAS, Grant PJ. A novel polymorphism in the factor XIII B subunit (His95Arg) relates to the dissociation of the A2B2 tetramer. Thromb Haemost 1999; 82: 111a.
  • 17 Ariens RA, Kohler HP, Mansfield MW, Grant PJ. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol 1999; 19: 2012-6.
  • 18 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
  • 19 Muszbek L, Adany R, Mikkola H. Novel Aspects of Blood Coagulation Factor XIII. I. Structure, Distribution, Activation, and Function. Crit Rev Cl Lab Sci 1996; 33: 357-421.
  • 20 Ichinose A. The physiology and biochemistry of factor III. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. (eds). Edinburgh: Churchill Livingstone; 1994: 531-46.
  • 21 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491-4.
  • 22 Kooistra T, Bosma PJ, Tons HAM, Van Den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 723-8.
  • 23 Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem 2000; 275: 20627-31.
  • 24 Brenn T. Genetic and environmental effects on coronary heart disease risk factors in Northern Norway. The cardiovascular disease study in Finnmark. Ann Hum Genet 1994; 58: 369-79.
  • 25 Friedlander Y, Elkana Y, Sinnreich R, Kark KD. Genetic and Environmental Sources of Fibrinogen Variability in Israeli Families: The Kibbutzim Family Study. Am J Hum Genet 1995; 56: 1194-206.
  • 26 Mitchell BD, Kammerer CM, Blangero J, Mahaney MC, Rainwater DL, Dyke B, Hixson JE, Henkel RD, Sharp RM, Comuzzie AG, VandeBerg JL, Stern MP, MacCluer JW. Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The San Antonio Family Heart Study Circulation 1996; 94 (02) 159-70.
  • 27 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic Function and Ischaemic Heart Disease: Principal Results of the Northwick Park Heart Study. Lancet 1986; 02: 533-7.
  • 28 Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and Factor VII in the Prediction of Coronary Risk. Results from the PROCAM Study in Healthy Men. Arterioscler Thromb Vasc Biol 1994; 14: 54-9.